INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Kandi Technologies Group, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Kandi Technologies Group, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kandi Technologies Group, Inc. (“Kandi” or “the Company”) (NASDAQ: KNDI) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Kandi is the subject of a report published by Hindenburg Research on November 30, 2020, titled: “Kandi: How This China-Based NASDAQ-Listed Company Used Fake Sales, EV Hype to Nab $160 Million From U.S. Investors.” Hindenburg claims its report is based on “extensive on-the-ground inspection at Kandi’s factories and customer locations in China, interviews with over a dozen former employees and business partners, and review of numerous litigation documents and international public records.” The report claims that 64% of the Company’s sales during the year were to undisclosed related parties. The report also alleges that the Company “has consistently booked revenue it cannot collect, a classic hallmark of fake revenue.”

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

[email protected]

www.schallfirm.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

Biohaven’s Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series

PR Newswire

MOORESVILLE, N.C., Dec. 2, 2020 /PRNewswire/ — Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry during the entire 2021 NASCAR Cup Series Season, starting at the season opener, the DAYTONA 500, at Daytona International Speedway in February 2021. Nurtec ODT was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in February 2020 and is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT) designed for rapid onset of action.

Rick Ware, former driver and current team owner, commented, “Rick Ware Racing welcomes Biohaven as our primary sponsor in the NASCAR Cup Series. I am ecstatic to have Nurtec ODT join the Rick Ware Racing family, and we just can’t wait for 2021 to get rolling. To have a sponsor help fund our team and at the same time, raise awareness about an acute treatment for migraine is a win for us and our fans. As the parent of a family member with migraine, I am particularly excited to help share the message about Nurtec ODT with the world so that many others can get relief. Racing is all about speed and we look forward to crossing the finish line with the Nurtec ODT No. 51 car.”

Nearly 40 million people in the U.S. suffer from migraine and the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).

Graham Goodrich, Biohaven Senior Vice President, Brand Marketing, stated, “Patients are at the center of everything that we race for at Biohaven and our partnership with Rick Ware Racing will help to continue to raise awareness about Nurtec ODT. Like many individuals, Rick’s racing family understands the impact of migraine and the need for fast migraine relief. Drivers who compete in races like the NASCAR Cup Series have to perform at the highest level under challenging mental and physical conditions. Like a race car driver, everyone wants to perform at their highest level but those who suffer from migraine know what it’s like to be forced to the sidelines. People with migraine need fast relief to get back on track and Biohaven is thrilled to partner with the Rick Ware Racing team on the Nurtec ODT No. 51 car for the 2021 NASCAR Cup Series.”

A single dose of Nurtec ODT has been shown to get people with migraine back to normal functioning within 60 minutes and have lasting effects for up to 48 hours.


Rick Ware Racing and Biohaven Participate in Military Salutes Program

As part of the NASCAR season, Rick Ware Racing and Biohaven will also participate in the Military Salutes Program and visit military bases across the country in a show of support and thanks to our troops. Through these visits, the two companies will interact with service members through mock pit stops, driver Q&As and photos. Active members of the military and veterans experience high levels of stress due to the challenges of their service, which can trigger migraine attacks. The Rick Ware Racing team and the Nurtec ODT No. 51 car will be visiting 50 military bases to honor the brave men and women who dedicate their lives to protect this great nation.

For additional information on Nurtec ODT, visit www.nurtec.com. Follow Rick Ware Racing, by visiting www.wareracing.com, and be sure to follow along on social media (Facebook, Twitter and/or Instagram). 

About Biohaven

Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s neuroinnovation portfolio includes FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer’s disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

About NURTEC ODT

NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily. For more information about NURTEC ODT, visit www.nurtec.com.

Indication

NURTEC™ ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

NURTEC ODT is not indicated for the preventive treatment of migraine.

Important Safety Information

Contraindications: Hypersensitivity to NURTEC ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received NURTEC ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with NURTEC ODT.

Drug Interactions: Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of NURTEC ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations:

Pregnant/breast feeding: It is not known if NURTEC ODT can harm an unborn baby or if it passes into breast milk. 
Hepatic impairment: Avoid use of NURTEC ODT in persons with severe hepatic impairment. 
Renal impairment: Avoid use in patients with end-stage renal disease.

Please click here for full
Prescribing Information.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Biohaven at 1-833-4Nurtec. 

Please click here for full Prescribing Information and Patient Information.

NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC

Biohaven Contact:
Vlad Coric, M.D.
Chief Executive Officer
[email protected]

Media Contact:
Mike Beyer
Sam Brown Inc.
[email protected]
312-961-2502

Rick Ware Racing Contact:
Kate Fegley
[email protected]

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohavens-nurtec-odt-partners-with-the-rick-ware-racing-team-in-the-2021-nascar-cup-series-301183822.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

Basware Adds Tools for Power Users in Accounts Payable Release to Improve Usability for Non-AP Staff

Basware Adds Tools for Power Users in Accounts Payable Release to Improve Usability for Non-AP Staff

Delivers Process Efficiencies for 100% User Adoption and 100% Spend Visibility

ESPOO, Finland–(BUSINESS WIRE)–
The latest release to the Basware (Nasdaq: BAS1V) Accounts Payable (AP) Automation solution introduces a standalone set of features designed for a dedicated user role outside of the AP department: the power user. Power users process more invoices than business users and perform complex invoice processing activities like AP clerks. Because of the complexity of their work and sheer number of invoices they process, this new release streamlines the user interface, which simplifies the process, increases user adoption, and ultimately provides the organization with better spend visibility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005125/en/

Tools for power users: empower decentralized business users with AP tools and deliver improvements in process efficiencies. Source: Basware

Tools for power users: empower decentralized business users with AP tools and deliver improvements in process efficiencies. Source: Basware

“The new features provide the missing link between business users and AP clerks to optimize efficiency in AP operations, allowing organizations to meet their AP key performance indicators,” states Olav Maas, Director AP Automation, Basware. “It’s difficult – nearly impossible – for a central AP team to understand all specific local requirements of purchases. Think of project managers in the construction industry purchasing construction materials and coordinating sub-contractors, or property managers in real estate with spend responsibilities such as cleaning and landscaping services – only they understand the particulars of these specific processes. They are also expected to complete the task of processing incoming invoices from those vendors. This means that they require sophisticated and precise tools to complete these tasks more efficiently.”

The additional tools, designed specifically for power users, provide this user type with a single, desktop-optimized view of all their tasks. It presents all relevant invoice information — image, coding and actions — in that one view, allowing them to match invoices with purchase orders and access coding tools with great ease. This streamlined interface delivers process efficiencies and ultimately improves user adoption because users can make quick decisions as they don’t need to click through multiple screens — or even navigate around on the one screen. By increasing the through-put of invoices, this technology leads to benefits such as the ability to capture early payment discounts and greater overall spend visibility for the company.

To learn more, read Achieving significant process efficiencies for power users managing decentralized AP tasks on the blog.

About Basware:

Basware is the only procure-to-pay and e-invoicing solution provider that empowers businesses with 100% spend visibility through 100% supplier connectivity and 100% data capture. Our cloud-based technology enables organizations to fully manage their spend, mitigate financial risk and reduce the cost of operations via automation. With the world’s largest open business network and an open technology ecosystem, we are uniquely positioned to deliver the solution required for Visible Commerce, which provides customers with complete transparency into all the flows of money, goods, and services around the world. A global company, Basware has offices in 14 countries and is traded on the Helsinki exchange (BAS1V: HE).

Jeanne Bernish

[email protected]

KEYWORDS: North Carolina Europe Finland United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Technology Software Banking Accounting

MEDIA:

Logo
Logo
Photo
Photo
Tools for power users: empower decentralized business users with AP tools and deliver improvements in process efficiencies. Source: Basware

Knoll Declares Cash Dividend

EAST GREENVILLE, Pa., Dec. 02, 2020 (GLOBE NEWSWIRE) — Knoll, Inc. (NYSE:KNL), a constellation of design-drive brands for the workplace and home, today announced that the Company’s Board of Directors declared a quarterly cash dividend of $0.06 per share payable December 31, 2020 to shareholders of record on December 15, 2020. 

The declaration and payment of dividends is subject to the discretion of the Board of Directors and depends on various factors, including our net income, restrictions in our credit facility, financial position, cash requirements and other factors deemed relevant by our Board of Directors.
  
About Knoll

Knoll, Inc. is a constellation of design-driven brands and people, working together with our clients in person and digitally to create inspired modern interiors. Our internationally recognized portfolio includes furniture, textiles, leathers, accessories, and architectural and acoustical elements. Our brands — Knoll Office, KnollStudio, KnollTextiles, KnollExtra, Spinneybeck | FilzFelt, Edelman Leather, HOLLY HUNT, DatesWeiser, Muuto, and Fully — reflect our commitment to modern design that meets the diverse requirements of high performance workplaces, work from home settings and luxury residential interiors. A recipient of the National Design Award for Corporate and Institutional Achievement from the Smithsonian`s Cooper-Hewitt, National Design Museum, Knoll, Inc. is aligned with the U.S. Green Building Council and the Canadian Green Building Council and can help organizations achieve the Leadership in Energy and Environmental Design (LEED) workplace certification. Our products can also help clients comply with the International Living Future Institute to achieve Living Building Challenge Certification, and with the International WELL Building Institute to attain WELL Building Certification. Knoll, Inc. is the founding sponsor of the World Monuments Fund Modernism at Risk program.

Contacts

Investors:
Charles Rayfield 
Senior Vice President and Chief Financial Officer
Tel 215 679-1703
[email protected]  

Media:
David E. Bright
Senior Vice President, Communications
Tel 212 343-4135
[email protected] 

 



LRN CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against K12 Inc.

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the securities of K12 Inc., (“K12” or the “Company”) (NYSE: LRN) between April 27, 2020 and September 18, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Eastern District of Virginia alleges violations of the Securities Exchange Act of 1934.

If you purchasedK12 securities, and/or would like to discuss your legal rights and options please visit K12 Shareholder Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; (4) and K12’s officers lacked a reasonable basis for their positive statements about the Company’s business, operations, and prospects.

On August 26, 2020, reports emerged that K12’s training for teachers in Miami-Dade County Public Schools, one of the largest school districts in the country, had been ineffective and unacceptable. On this news, K12’s shares fell by 7% over the course of two trading days.

When classes in Miami-Dade started on August 31, 2020, K12’s platform experienced major technical issues, disruptions, and a series of cyberattacks. In response, the district’s superintendent revealed that the district had never executed its $15.3 million contract with K12. On this news, the price of K12 shares fell by 10.5% over the course of two trading days.

A week later the Miami-Dade County Public School’s Board voted to terminate their contract with K12. On this news, the price of K12 common shares once again fell drastically, by 11.5% to close at $30.55 on September 10, 2020.

If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased K12securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/k12inc-lrn-shareholder-class-action-lawsuit-stock-fraud-333/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]



New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting

Adds More Evidence to Data Published in Lancet Oncology

CAMBRIDGE, Mass, Dec. 02, 2020 (GLOBE NEWSWIRE) —

FerGene Inc. today announced new data analyses results from the landmark Phase 3 clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3) for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). In the study, published in The Lancet Oncology on November 27, patients received nadofaragene firadenovec, an intravesical therapy given once every three months that is believed to target the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.1 The three new analyses from the pivotal study presented during the Society of Urologic Oncology (SUO) 21st Annual Meeting provide more evidence that nadofaragene firadenovec is a promising option for patients where BCG has failed.

The incidence and time to cystectomy was a key secondary objective of the Phase 3 study. A total of 40 (26.5%) patients underwent cystectomy, including 30 (29.1%) in the CIS +Ta/T1 cohort with median time to cystectomy being 8.87 months, and 10 (20.8%) in the HG Ta/T1 cohort with median time to cystectomy being 8.31 months. Patients who achieved complete response (CR) had significantly longer median time to cystectomy compared to those who did not (p=0.0432; 11.35 vs. 6.36 months, respectively. The estimated cystectomy-free survival among all treated patients was 64.5% at 24 months and was similar between the cohorts.2

The most common adverse events (AEs) observed in the Phase 3 study that occurred in patients in order of decreasing frequency were: instillation site discharge, fatigue, bladder spasm, micturition urgency, and hematuria. The discontinuation rate due to AEs was 1.9%.1

 “This data further reinforces the potential of nadofaragene firadenovec to help with the lack of treatment options available to high-grade NMIBC patients after BCG stops working for them,” said Robert Svatek, M.D., M.S.C.I., Professor and Chair, Department of Urology, UT Health, San Antonio, TX and nadofaragene firadenovec study investigator. If approved, nadoferegene firadenovec will be used by urologists in their offices giving us a new tool for the management of our patients.”

 

Patient Characteristics or Prior Treatment History Do Not Influence Response

The post hoc subgroup analysis of the Phase 3 study in high-grade, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) were based on the efficacy population of 151 patients. There were no significant differences in response rate at 3 and 15 months between males and females, age groups, BCG-refractory vs. BCG-relapsed, <3 or >3 prior course of BCG. There were also not significant differences between the subgroups in duration of response, except in the CIS+Ta/T1 cohort, where patients had received <3 prior courses of BCG had significantly longer duration of response compared to patients who received >3 courses (12.68 vs 4.96 months; p=0.0172).3

 

Significant Anti-Adenovirus Antibody Response Does Not Appear to Affect Patient Outcomes

Of the 151 patients included in the analysis for this secondary objective,129 had anti-adenoviral antibody titer results and were included in this analysis. Among the 55 patients who achieved CR in the  CIS+Ta/T1cohort, significantly more patients had positive post-baseline immunogenic response (43 vs. 8; p=0.0033). Similar results were found in the high-grade Ta/T1 cohort where among the 34 patients who remained free of high-grade recurrence at 3 months, significantly more patients had positive post-baseline immunogenic response (30 vs. 4; p=0.0003). At 15 months, the same trends were noted although the differences were not significant.4

“The research suggests that nadofaragene firadenovec may answer the need for additional targeted treatments that reduce the rate of bladder cancer recurrence and progression in patients where BCG has failed,” said Vikram Narayan, M.D., Assistant Professor of Urology, Emory University School of Medicine and Director of Urologic Oncology, Grady Memorial Hospital, Atlanta, GA and nadofaragene firadenovec study investigator.

In addition to these studies, a poster titled “Bladder Tumor Metabolic Alterations in Response to IFNA Gene Therapy Predict Clinical Disease Response and Identify Clinically Targetable Tumor Escape Pathways,” will be presented on nadofaragene firadenovec.5  

 

About Non-Muscle Invasive Bladder Cancer (NMIBC)

NMIBC is a form of bladder cancer which is present in the superficial layer of the bladder and has not invaded deeper into the bladder or spread to other parts of the body.6 It is estimated that there will be approximately 81,000 new cases of bladder cancer in the U.S. in 20207; 75% of these cases present as NMIBC.8 In patients with high-grade NMIBC, intravesical BCG is the recommended treatment; however, up to 50% of high-grade patients will experience disease recurrence within one year.6, 9 The outcome for BCG-unresponsive patients is poor, with chemotherapy and radiation or total cystectomy (complete removal of the bladder) often being the recommended next treatment options.10

 

About the Phase 3 Study

The Phase 3 study of nadofaragene firadenovec in 157 patients from 33 U.S. sites met its primary endpoint with more than half (53.4%) of CIS ± Ta/T1 patients (carcinoma in situ; with or without concomitant high-grade Ta or T1 disease) achieving a complete response (CR), all by three months.

Of the patients who achieved a CR, 45.5% continued to remain free of high-grade recurrence at 12 months. In the study, nadofaragene firadenovec was administered directly into the patient’s bladder once every three months by a healthcare professional. The long-term follow-up phase of the four-year study is ongoing, and patients are continuing to be monitored.1

“This additional evidence supports what we believe to be a positive benefit/risk profile of nadofaragene firadenovec in treating BCG-unresponsive NMIBC,” said Vijay Kasturi, M.D., Vice President of Medical Affairs at FerGene Inc. “In collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) we are pleased to advance the science that shows this novel gene therapy may fulfill a significant unmet medical need and has the potential to change the treatment paradigm for these patients.”

A Biologics License Application (BLA) for nadofaragene firadenovec is currently with the U.S. Food and Drug Administration (FDA).

 

About Nadofaragene Firadenovec

Nadofaragene firadenovec (rAd-IFN/Syn3) is an investigational gene therapy being developed as a treatment for patients with high-grade, BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene interferon alfa-2b, administered by catheter into the bladder once every three months. The vector enters the cells of the bladder wall, releasing the active gene to do its work. The internal gene/DNA machinery of the cells ‘picks up’ the gene and translates its DNA sequence, resulting in the cells secreting high quantities of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This novel gene therapy approach thereby turns the patient’s own bladder wall cells into interferon microfactories, enhancing the body’s natural defenses against the cancer. Nadofaragene firadenovec has been studied in a clinical trial program that includes 221 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit from additional BCG treatment.

 

About the SUO-CTC

Created, owned and operated by its members, the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) is a clinical research investigator network of over 500 members from more than 200 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO).The SUO-CTC pursues clinical trials, in concert with sponsors, to investigate therapeutic interventions which address urological cancers including, but not restricted to:  Bladder Cancer, Prostate Cancer and Renal Cancer. Together with industry, the SUO-CTC offers enhanced research options for ultimately delivering better quality of life to our patients. 

 

About FerGene Inc.

FerGene Inc. is a gene therapy company committed to revolutionizing the treatment of bladder cancer through its innovative science and unparalleled commitment to patient care. Founded in 2019, through a collaboration between Blackstone Life Sciences and Ferring Pharmaceuticals, FerGene Inc. is singularly focused on evolving the bladder cancer treatment landscape through its novel approach to gene therapy. A trusted partner to medical and advocacy communities, FerGene Inc. is dedicated to bringing new hope to a patient population which has seen little improvement in their standard of care over the past twenty years. For more information, please visit www.FerGene.com or engage with us on Twitter at @FerGeneBio or on LinkedIn.

 

# # #

© 2020 FerGene Inc. 20/11 US-ADST-2000117


1 Boorjian, S., Alemozaffar, M., Konety, B., Shore, N., Gomella, L., Kamat, A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2020;2045(20)30540. doi:101016/ S1470.

2 Narayan, V. Low Rate of Cystectomy and Delayed Median Time to Cystectomy Among Patients Who Achieved Complete Response with Nadofaragene Firadenovec. Society of Urologic Oncology 21st Annual Meeting. Poster #38.

3 Narayan, V. Subgroup Analyses of the Phase 3 Study of Intravesical Nadofaragene Firadenovec in Patients with High-Grade, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). Society of Urologic Oncology 21st Annual Meeting. Poster #23.

4 Narayan, V. Significant Anti-Adenovirus Antibody Response Positively Correlates with Efficacy in Patients Treated with Nadofaragene Firadenovec for High-Grade BCG-Unresponsive NMIBC. Society of Urologic Oncology 21st Annual Meeting.

5 Miest, T. Bladder Tumor Metabolic Alterations in Response to IFNα Gene Therapy Predict Clinical Disease Response and Identify Clinically Targetable Tumor Escape Pathways. Society of Urologic Oncology 21st Annual Meeting. Poster #39.

6 Sanli, O., Dobruch, J. Knowles, M. et al. Bladder cancer. Nat Rev Dis Primers. 3,17022 (2017) doi:10.1038/nrdp.2017.22.

7 American Cancer Society. Key Statistics for Bladder Cancer. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Updated 2020. Accessed March 5, 2020.

8 Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur urol. 2013;63(2):234-41. 10.1016./j.eururo.2012.07.033.

9 Kamat AM, Li R, O’Donnell MA, et al. Predicting response to intravesical Bacillus Calmette-Guérin immunotherapy: Are we there yet? A systemic review. Eur Urol. 2018;73(5):738-748. Doi:10.1016/j.eururo. 2017.10.003.

10 Marqueen K, et al. Identifying high surgical risk in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC). JNCI Cancer Spectrum. 2018 Oct; 2(4):pky075.

 



Cindy Romano
FerGene Inc. Communications
1-908-963-7827
[email protected]

Bring the Holidays Home with Baskin-Robbins’ December Holiday Cakes and Festive Flavor of the Month

Guest favorite Winter White Chocolate® returns as the December Flavor of the Month

PR Newswire

CANTON, Mass., Dec. 2, 2020 /PRNewswire/ –The ice cream experts at Baskin-Robbins have unwrapped a lineup of festive treats that are sure to make the season merry and bright. Brand new for the holidays, the Rosette Christmas Tree Cake spruces up any dessert table with rosettes of creamy, sweet icing and colorful sprinkles. Guests can customize their cake by choosing their favorite ice cream and cake flavors at their local Baskin-Robbins or online at BaskinRobbins.com.

Baskin-Robbins is also releasing a collection of ice cream flavors to deliciously enjoy the holiday season:

  • December’s Flavor of the Month, Winter White Chocolate®. Swirled with a rich cherry ribbon and bursting with bits of sweet cherry dipped in a chocolate flavored coating with a white chocolate flavored ice cream, this scoop is sure to be on everyone’s wish list.
  • Guests can dig into holiday decadence with the seasonal return of Baskin-Robbins’ classic Peppermint, loaded with peppermint pieces in a pink peppermint ice cream. This seasonal flavor also makes the perfect shake!
  • Eggnog flavored ice cream with hints of rum and nutmeg and Butterscotch Crunch with butterscotch pieces and a toffee-flavor ribbon, are available in pre-packed quarts to-go.

“We’re excited to share a taste of the season with our collection of customizable holiday cakes and festive ice cream flavors,” said Shannon Blakely, Vice President of Marketing, Baskin-Robbins U.S. and Canada. “We also invite our guests to order a treat for themselves or send a surprise to a loved one through our delivery partners DoorDash and Uber Eats – or with an e-gift card ordered through our app.”

Guests can also celebrate the holidays with returning favorites like the Reindeer Cake, featuring an adorable reindeer with chocolate snout, antlers and holly garnish, the Snowman Cake, bundled up for the season in festive holiday icing or the Winter WonderlandCake, decorated in beautiful icy blues, a white chocolate-drizzled edge, and topped with sparkling glitter. Plus, Baskin-Robbins’ new Modern Wreath Cake and Winter Forest Cake, which both feature iconic holiday designs that are sure to make the season merry. Each cake can be customized to include guests’ favorite ice cream and cake flavors.

Cake orders can be placed online at BaskinRobbins.com, through the Baskin-Robbins mobile app or by visiting or calling your local Baskin-Robbins restaurant. Gift cards are also available for purchase at your local Baskin-Robbins, in the Baskin-Robbins mobile app and online at BaskinRobbins.com.

For those looking for a sweet post-holiday treat, guests who spend $10 or more on Baskin-Robbins through Uber Eats between December 28, 2020 and January 3, 2021 will receive a $0 delivery fee with no promo code necessary.*

The vast majority of Baskin-Robbins stores remain open across the country and have enhanced preventative health and safety measures in place. In an ongoing effort to help keep guests and restaurant employees safe, Baskin-Robbins is currently limiting service to drive-thru, carry-out and curbside pick-up at select locations, in addition to delivery at participating locations with Uber Eats and DoorDash. Guests can order and pay contactless through the Baskin-Robbins mobile app for a quick, grab-and-go experience.

For more information about Baskin-Robbins’ wide variety of premium ice cream flavors and frozen desserts, visit www.BaskinRobbins.com or follow along on Facebook (www.facebook.com/BaskinRobbinsUS), Twitter (www.twitter.com/BaskinRobbins) and Instagram (www.instagram.com/BaskinRobbins).

*Offer expires at 11:55pm PT on 1/3/21. The offer is valid for a $0 Delivery Fee. A minimum order of $10 before taxes and fees is required. Taxes and Service Fee still apply. A Small Order Fee may apply. Offer may not be combined with other offers. See the Uber Eats app for details and location availability. Valid only in the United States.

About Baskin-Robbins
Named a top snack and beverage franchise in the United States by Nation’s Restaurant News in 2019, Baskin-Robbins is the world’s largest chain of ice cream specialty shops. Baskin-Robbins creates and markets innovative, premium hard scoop ice cream, a full range of beverages and a delicious lineup of desserts including custom ice cream cakes, the Polar Pizza® Ice Cream Treat and take-home ice cream quarts and pints, providing quality and value to consumers at nearly 7,900 retail shops in 52 countries worldwide. Baskin-Robbins was founded in 1945 by two ice cream enthusiasts whose passion led to the creation of more than 1,300 ice cream flavors and a wide variety of delicious treats. Headquartered in Canton, Mass., Baskin-Robbins is part of the Dunkin’ Brands Group, Inc. (Nasdaq:DNKN) family of companies. For more information, visit www.BaskinRobbins.com.

MEDIA CONTACT:

Kelly Deininger

Dunkin’ Brands
781-737-5200
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bring-the-holidays-home-with-baskin-robbins-december-holiday-cakes-and-festive-flavor-of-the-month-301183721.html

SOURCE Baskin-Robbins

Seabourn Announces 2021 Signature Savings Event, With Significant Benefits And Values On Select 2021-2022 Voyages

PR Newswire

SEATTLE, Dec. 2, 2020 /PRNewswire/ — Seabourn, the ultra-luxury resort at sea, is encouraging guests to rediscover the “Extraordinary Worlds” with its 2021 Signature Savings Event, featuring exceptional offers and an array of value-added amenities on select summer 2021 and winter/spring 2022 voyages across its award-winning ultra-luxury fleet, including Seabourn Venture, the line’s first ultra-luxury purpose-built expedition ship launching in December 2021.

The annual event kicks off at the start of the holiday season on December 2, 2020 and will run through March 1, 2021, boasting a variety of significant benefits such as suite upgrades, shipboard credits and generous internet packages. Guests can rediscover the world, from cosmopolitan cities to picturesque, seaside towns, while traveling in ultra-luxury style with Seabourn. Depending on the individual voyage, event benefits include the following*:

  • Veranda for Ocean View Suite upgrades
  • Up to three category Veranda Suite upgrades
  • Up to $1,000 USD shipboard credit per suite
  • Up to 900-minute internet Package per guest
  • 50% Reduced Deposit
  • PLUS: Book a Penthouse or Premium Suite to receive up to $2,000 USD shipboard credit per suite and an Unlimited Internet Package per suite. Penthouse and Premium suites provide even more space and more amenities for guests who sail on board, with separate bedrooms and ample space to entertain in-suite.

*
Terms and Conditions apply. Check the Seabourn

website

 for full details.

“With the exceptional value and savings that our Signature Savings Event has to offer, we are encouraging our guests to make those travel plans that they have put on hold all year,” said Steve Smotrys, Seabourn’s vice president of global sales. “We know they are eager to pack their bags and travel to some of the most extraordinary destinations, all in the comfort and ultra-luxury style found with Seabourn, where the experience and people on board are unforgettable.”

For even greater value, Seabourn’s “Signature Savings Event” may be combined with other Seabourn promotions, including the line’s “Early Bonus Savings” promotion, which offers an additional 10 percent savings off the base cruise fare to guests who pay their booking in full by February 1, 2021. Other combinable promotions include group rates, solo traveler offers, and Seabourn Club Savings, which provides an extra five percent savings to Seabourn Club Members. In addition, Seabourn has extended its “Book with Confidence” policy through January 31, 2021, providing even more flexibility, assurance and options for travelers to cancel their booking up to 30 days prior to departure on any new bookings and receive a future cruise credit. 

Seabourn’s Signature Savings Event applies to select worldwide cruises in the Mediterranean, Northern Europe, Antarctica and Patagonia, Alaska, Australia and New Zealand, Asia, Arabia & India, the Caribbean, Panama Canal, South America, Pacific Coast, and transatlantic voyages, as well as expedition voyages on Seabourn Venture. A complete listing of the sailings, savings and amenities can be viewed on Seabourn’s website.

Seabourn represents the pinnacle of ultra-luxury travel. Our all-inclusive, boutique ships offer all-suite accommodations with oceanfront views; award-winning dining; complimentary premium spirits and fine wines available at all times; renowned service provided by an industry-leading crew; a relaxed, sociable atmosphere that makes guests feel at home; a pedigree in expedition travel through the Ventures by Seabourn program and two new ultra-luxury purpose-built expedition ships coming in 2021 and 2022. Seabourn takes travelers to every continent on the globe travel with more than 400 ports including marquee cities and lesser-known ports and hideaways. The line is also the official cruise partner of UNESCO World Heritage.

Guests of Seabourn experience extraordinary offerings and programs, including partnerships with leading entertainers, dining, personal health and wellbeing, and engaging speakers. 

For reservations or more details, please contact a professional travel advisor; call Seabourn at 1-800-929-9391 or visit www.seabourn.com. A dedicated shore excursion call center is available for guests at 1-800-984-3225.




Click-to-Tweet





:






Rediscover the “Extraordinary Worlds” with @SeabournCruise’s 2021 Signature Savings Event featuring exceptional offers and value-added amenities on select voyages including the line’s first expedition ship #SeabournVenture. Book today:



https://bit.ly/SignatureSavings


About Seabourn:

Ultra-luxury Seabourn currently operates a fleet of five modern ships with two under construction and is a proud member of World’s Leading Cruise Lines. The exclusive alliance also includes Carnival Cruise Lines, Holland America Line, Princess Cruises, Cunard Line, Costa Cruises, AIDA, P&O Cruises UK, and P&O Cruises Australia. Seabourn is a brand of Carnival Corporation and plc (NYSE/LSE: CCL and NYSE: CUK). Seabourn is the official cruise partner of UNESCO World Heritage under a multi-year agreement to help promote sustainable tourism at World Heritage sites around the world. Our highest responsibility and top priorities are compliance, environmental protection and the health, safety and well-being of our guests, crew, shoreside employees, and the people and communities our ships visit.

Find Seabourn on Twitter, Facebook, Instagram, YouTube and Pinterest.

Notes to Editors:
Seabourn is consistently ranked among the world’s top travel choices by professional critics and the discerning readers of prestigious travel publications such as Departures, Travel + Leisure and Condé Nast Traveler. Its stylish, distinctive cruising vacations are renowned for:

  • Intimate ships with a private club atmosphere
  • Intuitive, personalized service provided by staff passionate about exceeding guests expectations
  • Curated voyages to all seven continents delivering award-winning experiences
  • All ocean-front suites, luxuriously appointed
  • Complimentary premium spirits and fine wines available on board at all times
  • Welcome Champagne and complimentary in-suite bar stocked with your preferences
  • Tipping is neither required, nor expected
  • Finest resort at sea that is masterfully designed 
  • World-class dining, further enhanced through a culinary partnership with Chef Thomas Keller
  • All dining venues are complimentary, dine where, when and with whom you wish
  • Seabourn Conversations, connecting with visionary experts
  • Ventures by Seabourn™, optional shore excursions, enhance and extend your experience in select destinations*^
  • Select purposeful and sustainable travel experiences in partnership with UNESCO*
  • Spa & Wellness with Dr. Andrew Weil, featuring an exclusive mindful living program*
  • An evening entertainment experience in collaboration with Sir Tim Rice†
  • Committed to environmental stewardship and sustainability

*Optional programs, for additional charge
^Available on Seabourn Odyssey, Seabourn Sojourn, Seabourn Quest, Seabourn Encore, Seabourn Ovation
†Not available on board Seabourn Venture

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/seabourn-announces-2021-signature-savings-event-with-significant-benefits-and-values-on-select-2021-2022-voyages-301183825.html

SOURCE Seabourn

SiriusXM and 88rising Launch 88rising Radio, An All-Asian Artist Music Channel

First 24/7 radio channel in North America dedicated to showcasing Asian artists from around the world

Daily programming will include interviews, performances, and music from the biggest Asian stars and emerging artists across Asia

Full-time channel hosted by 88rising talent and founder

Pandora to launch complementary 88rising Radio station

PR Newswire

NEW YORK, Dec. 2, 2020 /PRNewswire/ –SiriusXM and 88rising, the pioneering Asian-focused music and media company, announced today the launch of 88rising Radio, the first all-Asian, multi-genre music radio channel available across the U.S. The channel will debut tomorrow, December 3 at 12 p.m. ET on SiriusXM’s channel 305.

SiriusXM collaborated on the creation of the channel with 88rising, the Los Angeles-based artist collective and media platform, which represents the most cutting-edge artists from Asia, and bridges Eastern and Western youth culture. 88rising, founded by Sean Miyashiro, will develop, curate and present the 24/7 channel. Pandora will launch a complementary 88rising Radio station in January which will include select tracks and exclusive artist audio messages from the SiriusXM channel.

88rising Radio will broadcast an array of music rarely heard on American radio, from the biggest pop songs topping the charts across Asia, to current emerging discoveries, and feature artists from South Korea, China, Japan, the Philippines, Indonesia, Vietnam, Thailand and more. Artists such as BTS, Joji, BLACKPINK, TWICE, Rich Brian, Peggy Gou, Jackson Wang, beabadoobee, Iñigo Pascual, NIKI and many more will be included. When social distancing is no longer required, the channel will also provide a unique platform for touring artists to visit, conduct interviews and interact with listeners, and perform live-on-air at the SiriusXM studios in Los Angeles and New York.

“SiriusXM is known for compelling content and having a pulse on American pop culture,” said Miyashiro, CEO and founding member of 88rising. “Collaborating on this channel has been truly organic and in synergy with our goals on bringing 88’s foresight regarding Asian culture and its impact to American listeners through our new channel, 88rising Radio.”

Sean Miyashiro and his team are creating one of the most remarkable creative hubs in music today,” said Scott Greenstein, President and Chief Content Officer of SiriusXM. “88rising is a pioneering force bridging East and West, with unquestionable success and credibility in bolstering cutting-edge Asian music culture. It is exciting to have 88rising join the SiriusXM lineup, where its music, content, and curation of 88rising Radio channel will have it on par with any of our great music channels today.”

The groundbreaking, first-of-its-kind commercial-free music channel will debut with an all-star 24-hour takeover by acclaimed and closely followed Asian and Asian-American artists. Beginning at 3 p.m. ET, on December 3, 88rising artists and Asian talent from around the world will take over the channel, guest DJing the songs that define them, alongside some of the hottest Asian music acts and their own live performances.  Participating artists will include Yuna, Dumbfoundead, beabadoobee, Phum Viphurit, Japanese Breakfast, Keshi and more.

88rising Radio will launch with daily programming including, Dumb Early, hosted by rapper/actor Dumbfoundead, and SOSUPERSOUNDS, hosted by DJ/singer SOSUPERSAM. In 2021, listeners will also get the first global Asian countdown show, The Greatest 8, hosted by Miyashiro and Joy F*ck Club, a six-part comedy interview series hosted by comedian Joel Kim Booster.

Asian rap icon Dumbfoundead will wake America up to the latest in Asian pop culture and music news while serving up a menu of fresh hits on Dumb Early.  DJ SOSUPERSAM will introduce listeners to the best Asian music on an eclectic afternoon road trip through new music discoveries and the latest hits on SOSUPERSOUNDS.  On The Greatest 8, Miyashiro will count down the eight hottest new tracks of the week, while interviewing the superstars of Asian music in-studio. The Joy F*ck Club will give listeners a front row seat inside Booster’s imaginary comedy club, where emerging and established Asian comics debate and dispel Asian stereotypes, as well as share their own hilarious stories on their Asian-American experience.

Starting today at 7 p.m. ET, fans can tune into DOUBLE HAPPINESS Global Holiday Festival presented by 88rising on www.siriusxm.com/88rising, for a sneak peak of what is to come on 88rising Radio.  The inaugural festival will DOUBLE HAPPINESS featuring never-before-seen performances, festive holiday covers, and exclusive video premieres from top Asian artists including headliners like Anderson .Paak and Knxwledge’s prodigious musical duo NxWorries, K-Pop boy band sensation ATEEZ, and K-Pop phenomenon CHUNG HA. Hosted in Los Angeles by rapper Dumbfoundead, DOUBLE HAPPINESS will feature 30+ artists hailing from 8 countries around the world. For a full list of artists and more information visit https://easternstandardti.me.

SiriusXM subscribers can listen to 88rising Radio beginning tomorrow on channel 305 in vehicles and via SiriusXM online or on the SiriusXM app on a wide variety of connected devices, including smart TVs, devices with Amazon Alexa or the Google Assistant, Apple TV, PlayStation, Roku, Sonos speakers and more. The SiriusXM app also offers additional features such as SiriusXM video, Pandora stations and the SiriusXM App library with more than 10,000 hours of archived shows, exclusive music performances, interviews and audio documentaries. SiriusXM has special offers for new subscribers including three months of a SiriusXM Premier Streaming subscription for Free. To see Offer Details and to subscribe, visit www.SiriusXM.com/free3.


About SiriusXM

Sirius XM Holdings Inc. (NASDAQ: SIRI) is the leading audio entertainment company in the U.S., and the premier programmer and platform for subscription and digital advertising-supported audio products. Pandora, a subsidiary of SiriusXM, is the largest ad-supported audio entertainment streaming service in the U.S. SiriusXM and Pandora’s properties reach more than 150 million listeners, the largest addressable audience in the U.S., across all categories of digital audio – music, sports, talk, and podcasts. SiriusXM’s acquisitions of Stitcher and Simplecast, alongside industry-leading ad tech company AdsWizz, make it a leader in podcast hosting, production, distribution, analytics and monetization. SiriusXM, through Sirius XM Canada Holdings, Inc., also offers satellite radio and audio entertainment in Canada. In addition to its audio entertainment businesses, SiriusXM offers connected vehicle services to automakers. For more about SiriusXM, please go to: www.siriusxm.com.

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

The following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements:  the current coronavirus (COVID-19) pandemic is adversely impacting our business;
 our substantial competition that is likely to increase over time; our efforts to attract and retain subscribers and listeners, or convert listeners into subscribers, which may not be successful, and may adversely affect our business; our Pandora ad-supported business has suffered a loss of monthly active users, which may adversely affect our Pandora business; privacy and data security laws and regulations may hinder our ability to market our services, sell advertising and impose legal liabilities; we engage in extensive marketing efforts and the continued effectiveness of those efforts are an important part of our business; consumer protection laws and our failure to comply with them could damage our business; a substantial number of our Sirius XM subscribers periodically cancel their subscriptions and we cannot predict how successful we will be at retaining customers; our ability to profitably attract and retain subscribers to our Sirius XM service as our marketing efforts reach more price-sensitive consumers is uncertain; our failure to convince advertisers of the benefits of our Pandora ad-supported service could harm our business; if we are unable to maintain revenue growth from our advertising products, particularly in mobile advertising, our results of operations will be adversely affected; if we fail to accurately predict and play music, comedy or other content that our Pandora listeners enjoy, we may fail to retain existing and attract new listeners; if we fail to protect the security of personal information about our customers, we could be subject to costly government enforcement actions and private litigation and our reputation could suffer; interruption or failure of our information technology and communications systems could impair the delivery of our service and harm our business; we rely on third parties for the operation of our business, and the failure of third parties to perform could adversely affect our business; our business depends in part upon the auto industry; our Pandora business depends in part upon consumer electronics manufacturers; the market for music rights is changing and is subject to significant uncertainties; our ability to offer interactive features in our Pandora services depends upon maintaining licenses with copyright owners; the rates we must pay for “mechanical rights” to use musical works on our Pandora service have increased substantially and these new rates may adversely affect our business; failure of our satellites would significantly damage our business; our Sirius XM service may experience harmful interference from wireless operations; failure to comply with FCC requirements could damage our business; economic conditions, including advertising budgets and discretionary spending, may adversely affect our business and operating results; if we are unable to attract and retain qualified personnel, our business could be harmed; we may not realize the benefits of acquisitions or other strategic investments and initiatives, including the acquisition of Pandora; our use of pre-1972 sound recordings on our Pandora service could result in additional costs; we may from time to time modify our business plan, and these changes could adversely affect us and our financial condition; we have a significant amount of indebtedness, and our debt contains certain covenants that restrict our operations; our facilities could be damaged by natural catastrophes or terrorist activities; the unfavorable outcome of pending or future litigation could have an adverse impact on our operations and financial condition; failure to protect our intellectual property or actions by third parties to enforce their intellectual property rights could substantially harm our business and operating results; some of our services and technologies may use “open source” software, which may restrict how we use or distribute our services or require that we release the source code subject to those licenses; rapid technological and industry changes and new entrants could adversely impact our services; existing or future laws and regulations could harm our business; we may be exposed to liabilities that other entertainment service providers would not customarily be subject to; our business and prospects depend on the strength of our brands; we are a “controlled company” within the meaning of the NASDAQ listing rules and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements; while we currently pay a quarterly cash dividend to holders of our common stock, we may change our dividend policy at any time; and our principal stockholder has significant influence, including over actions requiring stockholder approval, and its interests may differ from the interests of other holders of our common stock. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 30, 2020, which are filed with the Securities and Exchange Commission (the “SEC”) and available at the SEC’s Internet site (

http://www.sec.gov

). The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this communication.

Source: SiriusXM

Media contacts for SiriusXM:

Angela Burke

[email protected]

Carolina Dubon

[email protected] 


Media Contacts for 88rising:


Sarah Agate

301-807-7182
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/siriusxm-and-88rising-launch-88rising-radio-an-all-asian-artist-music-channel-301183743.html

SOURCE Sirius XM Holdings Inc.

Sonesta Announces The Addition Of Over 100 Hotels To Portfolio

Sonesta Launches New Brand, Sonesta Simply Suites

PR Newswire

NEWTON, Mass., Dec. 2, 2020 /PRNewswire/ — Sonesta International Hotels Corporation announced the addition of 102 properties to its global hotel portfolio. 99 of the hotels have already been reflagged as Sonesta on 12/1, and the three remaining hotels, located in Canada and Puerto Rico, will be reflagged later in the month. All the hotels are owned by Service Properties Trust (Nasdaq: SVC).

As a result of this expansion, Sonesta will be introduced in over a dozen new North American cities, including:

Expanding upon its existing hotel brands: Royal Sonesta, distinctive full-service destinations; Sonesta Hotels & Resorts, full-service hotels and resorts, andSonesta ES Suites, Sonesta premier extended stay accommodations; Sonesta has announced a new brand Sonesta Simply Suites, a more focused extended-stay offering. Sonesta Simply Suites will initially launch with over 60 locations, making it one of the largest U.S. hotel brand launches in history.

The Sonesta expansion also includes an extended presence in a number of key U.S. cities and states, including:

  • Atlanta – seven new hotels were added, increasing Sonesta’s presence to 12 total hotels in the greater Atlanta area.
  • Chicago – seven new hotels were added, including Royal Sonesta Chicago River North and Allegro Royal Sonesta Chicago West Loop increasing Sonesta’s presence to 12 total hotels in the Chicago area.
  • Detroit – four new hotels were added, increasing Sonesta’s presence to six total hotels in the greater Detroit area.
  • Florida – six new properties were added, increasing brand presence in the state to nine.
  • Houston – four new Sonesta Simply Suites were added, increasing the company’s presence to seven hotels in Sonesta’s Houston portfolio and 19 hotels in the state of Texas.

“I am excited to have the opportunity to expand our national presence, including the addition of over a dozen new destinations, including our first locations in Washington D.C., Los Angeles, Dallas, and Las Vegas.  We are also entering the Canadian market for the first time with two Toronto hotels, and adding a resort in San Juan, Puerto Rico,” said Carlos Flores, President and CEO, Sonesta International Hotels Corporation. “The introduction of our new brand, Sonesta Simply Suites, will allow us to strengthen our foothold in the extended stay arena catering to travelers who require a modest longer-term option.”

Sonesta is one of the fastest growing hospitality companies in the U.S., growing its portfolio by almost 350%. Sonesta now operates nearly 300 properties across seven brands operating in the U.S., Canada, Chile, Colombia, Ecuador, Egypt, Peru, and St. Maarten. Sonesta hotels, resorts and suites can be found in many of the most traveled U.S. destinations, including Atlanta, Austin, Boston, Chicago, Hilton Head, Houston, Los Angeles, New Orleans, Portland, San Francisco, San Jose, Seattle, St. Louis, and Washington D.C.. For more about Sonesta and its locations, visit Sonesta.com or call +1.617.315.9200 or 800.Sonesta (800.766.3782) in the U.S. and Canada. Follow us on social media @SonestaHotels.

* High-resolution images are available at www.sonesta.com/media for all Sonesta hotels.

Media Contact:
Libby Foxman, Weber Shandwick for Sonesta [email protected] / 212-546-7838

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sonesta-announces-the-addition-of-over-100-hotels-to-portfolio-301183225.html

SOURCE Sonesta International Hotels Corporation